Lionheart Health Recognized as Top Implantable Stimulator Developer by MedTech Outlook

Lionheart Health, Inc., a pioneering biotech and medical device company, has been honored by MedTech Outlook as the Top Implantable Stimulator Developer of the Year. This accolade highlights the company's groundbreaking KlothoImplant™ and MicroImplant™ technologies, which utilize bioelectric signaling to control regenerative protein expression, offering new hope for healthspan extension and organ regeneration.

The technologies developed by Lionheart Health are designed to deliver precise bioelectric signals that can stimulate the release of proteins critical for stem cell homing, muscle building, blood vessel growth, and reducing inflammation. According to Brian Lasater, Chief Technology Officer at Lionheart Health, these micro implant stimulators represent a significant leap forward in medical science, capable of reversing aging effects and fighting chronic inflammation.

Collaborating with Leonhardt Ventures LLC, Lionheart Health has expanded its bioelectric stimulation platform to target a wide range of applications, including the regeneration of vital organs and the restoration of hearing. The company's portfolio includes a variety of devices, from benchtop stimulators to miniaturized implants, all of which have undergone rigorous testing for safety and efficacy.

MedTech Outlook's recognition of Lionheart Health underscores the potential of implantable stimulators to revolutionize healthcare. With over 500 issued and pending patents, and multiple FDA clearances, Lionheart Health is at the forefront of developing technologies that could significantly impact healthspan and longevity. The company's recent selection as a Top 40 semifinalist in the XPRIZE Healthspan competition further attests to its innovative contributions to the field.

For more information on Lionheart Health's technologies, visit https://www.LionheartLongevity.com, https://www.lionhearthealthstim.com, and https://www.LeonhardtVentures.com.